Suppr超能文献

人类诺如病毒培养系统及其在抗病毒研究中的应用。

Human norovirus cultivation systems and their use in antiviral research.

机构信息

Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan.

Laboratory of Virus Control, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.

出版信息

J Virol. 2024 Apr 16;98(4):e0166323. doi: 10.1128/jvi.01663-23. Epub 2024 Mar 12.

Abstract

Human norovirus (HuNoV) is a major cause of acute gastroenteritis and foodborne diseases, affecting all age groups. Despite its clinical needs, no approved antiviral therapies are available. Since the discovery of HuNoV in 1972, studies on anti-norovirals, mechanism of HuNoV infection, viral inactivation, etc., have been hampered by the lack of a robust laboratory-based cultivation system for HuNoV. A recent breakthrough in the development of HuNoV cultivation systems has opened opportunities for researchers to investigate HuNoV biology in the context of HuNoV infections. A tissue stem cell-derived human intestinal organoid/enteroid (HIO) culture system is one of those that supports HuNoV replication reproducibly and, to our knowledge, is most widely distributed to laboratories worldwide to study HuNoV and develop therapeutic strategies. This review summarizes recently developed HuNoV cultivation systems, including HIO, and their use in antiviral studies.

摘要

人类诺如病毒(HuNoV)是急性胃肠炎和食源性疾病的主要病因,影响所有年龄段。尽管有临床需求,但目前尚无获得批准的抗病毒疗法。自 1972 年发现 HuNoV 以来,由于缺乏稳健的基于实验室的 HuNoV 培养系统,针对抗诺如病毒药物、HuNoV 感染机制、病毒失活等方面的研究受到了阻碍。最近,HuNoV 培养系统的开发取得了突破,为研究人员在 HuNoV 感染背景下研究 HuNoV 生物学提供了机会。一种组织干细胞衍生的人类肠道类器官(HIO)培养系统就是其中之一,它能够重复性地支持 HuNoV 复制,并且据我们所知,它在全球范围内分布最广,被用于研究 HuNoV 并开发治疗策略。本综述总结了最近开发的 HuNoV 培养系统,包括 HIO,及其在抗病毒研究中的应用。

相似文献

1
Human norovirus cultivation systems and their use in antiviral research.
J Virol. 2024 Apr 16;98(4):e0166323. doi: 10.1128/jvi.01663-23. Epub 2024 Mar 12.
2
Dasabuvir Inhibits Human Norovirus Infection in Human Intestinal Enteroids.
mSphere. 2021 Dec 22;6(6):e0062321. doi: 10.1128/mSphere.00623-21. Epub 2021 Nov 3.
3
Replication of human noroviruses in stem cell-derived human enteroids.
Science. 2016 Sep 23;353(6306):1387-1393. doi: 10.1126/science.aaf5211. Epub 2016 Aug 25.
5
Standardization of an antiviral pipeline for human norovirus in human intestinal enteroids demonstrates nitazoxanide has no to weak antiviral activity.
Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0063623. doi: 10.1128/aac.00636-23. Epub 2023 Oct 3.
6
Inhibitory effect of Ephedra herba on human norovirus infection in human intestinal organoids.
Biochem Biophys Res Commun. 2023 Sep 3;671:200-204. doi: 10.1016/j.bbrc.2023.05.127. Epub 2023 Jun 2.
7
New Insights and Enhanced Human Norovirus Cultivation in Human Intestinal Enteroids.
mSphere. 2021 Jan 27;6(1):e01136-20. doi: 10.1128/mSphere.01136-20.
8
Nitazoxanide Inhibits Human Norovirus Replication and Synergizes with Ribavirin by Activation of Cellular Antiviral Response.
Antimicrob Agents Chemother. 2018 Oct 24;62(11). doi: 10.1128/AAC.00707-18. Print 2018 Nov.
9
Bile acid-sensitive human norovirus strains are susceptible to sphingosine-1-phosphate receptor 2 inhibition.
J Virol. 2024 Jul 23;98(7):e0202023. doi: 10.1128/jvi.02020-23. Epub 2024 Jun 17.

引用本文的文献

1
BTP2 restricts Tulane virus and human norovirus replication independent of store-operated calcium entry.
J Virol. 2025 Jun 17;99(6):e0044425. doi: 10.1128/jvi.00444-25. Epub 2025 May 29.
2
Navigating Uncertainties in RT-qPCR and Infectivity Assessment of Norovirus.
Food Environ Virol. 2025 Mar 8;17(1):22. doi: 10.1007/s12560-024-09632-0.
3
Norovirus replication, host interactions and vaccine advances.
Nat Rev Microbiol. 2025 Jun;23(6):385-401. doi: 10.1038/s41579-024-01144-9. Epub 2025 Jan 17.
4
Insights into human norovirus cultivation in human intestinal enteroids.
mSphere. 2024 Nov 21;9(11):e0044824. doi: 10.1128/msphere.00448-24. Epub 2024 Oct 15.
5
Machine Learning and Imputation to Characterize Human Norovirus Genotype Susceptibility to Sodium Hypochlorite.
Food Environ Virol. 2024 Dec;16(4):492-505. doi: 10.1007/s12560-024-09613-3. Epub 2024 Sep 11.

本文引用的文献

1
Molnupiravir inhibits human norovirus and rotavirus replication in 3D human intestinal enteroids.
Antiviral Res. 2024 Mar;223:105839. doi: 10.1016/j.antiviral.2024.105839. Epub 2024 Feb 17.
2
Favipiravir induces HuNoV viral mutagenesis and infectivity loss with clinical improvement in immunocompromised patients.
Clin Immunol. 2024 Feb;259:109901. doi: 10.1016/j.clim.2024.109901. Epub 2024 Jan 12.
3
Rotavirus-mediated DGAT1 degradation: A pathophysiological mechanism of viral-induced malabsorptive diarrhea.
Proc Natl Acad Sci U S A. 2023 Dec 19;120(51):e2302161120. doi: 10.1073/pnas.2302161120. Epub 2023 Dec 11.
4
Challenges for estimating human norovirus infectivity by viability RT-qPCR as compared to replication in human intestinal enteroids.
Int J Food Microbiol. 2024 Feb 2;411:110507. doi: 10.1016/j.ijfoodmicro.2023.110507. Epub 2023 Nov 24.
7
Standardization of an antiviral pipeline for human norovirus in human intestinal enteroids demonstrates nitazoxanide has no to weak antiviral activity.
Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0063623. doi: 10.1128/aac.00636-23. Epub 2023 Oct 3.
8
Non-Polio Enterovirus C Replicate in Both Airway and Intestine Organotypic Cultures.
Viruses. 2023 Aug 27;15(9):1823. doi: 10.3390/v15091823.
10
Murine Norovirus: Additional Protocols for Basic and Antiviral Studies.
Curr Protoc. 2023 Jul;3(7):e828. doi: 10.1002/cpz1.828.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验